.jetcityimage/iStock Editorial using Getty Images Morgan Stanley has actually opted for Eli Lilly (NYSE: LLY) as its top biopharma pick for 2025 and also rated another 9 names in the area as obese. The investment financial institution stated in a keep in mind that it remains to feel “diabesity is set to come to be.